Semaglutide, the active ingredient in Ozempic, has a strong safety record from large clinical trials and years of real-world use, but “safe” comes with meaningful caveats that depend on your health history, how you use it, and how long you stay on it. The drug was originally approved for type 2 diabetes, and its use for weight loss specifically falls under a different brand name (Wegovy) at a higher dose, though Ozempic is widely prescribed off-label for the same purpose. The risks are real and range from common but manageable gut symptoms to rarer but serious complications involving the pancreas, gallbladder, and eyes. Understanding which risks apply to you, and which are overhyped, is worth the time before you fill a prescription.
How Semaglutide Produces Weight Loss
Semaglutide mimics a gut hormone called GLP-1, which your body releases naturally after eating. This hormone slows the rate at which your stomach empties, dials down hunger signals in the brain, and promotes a feeling of fullness after smaller meals.1PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery A systematic review of trials in people without diabetes confirmed that semaglutide consistently reduced hunger scores and total calorie intake compared with placebo, and that these appetite effects tracked closely with the weight people lost.2Epidemiology and Health Data Insights. Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review In one trial that directly measured food intake under lab conditions, participants on semaglutide ate less, felt fuller, and reported fewer food cravings than those on placebo.3PubMed Central. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity The upshot is that the drug works primarily by making you want to eat less, not by burning extra calories or blocking nutrient absorption.
How Much Weight People Actually Lose
The landmark STEP 1 trial, which enrolled over 1,900 adults with obesity or overweight, found that participants on once-weekly semaglutide lost roughly 15% of their body weight over 68 weeks, compared with about 2.4% in the placebo group.4PubMed. Once-Weekly Semaglutide in Adults with Overweight or Obesity About half the semaglutide group lost 15% or more. Those are averages, and individual results vary widely, but the trial established semaglutide as one of the most effective weight-loss medications available at the time.
Longer follow-up data from the STEP 5 trial showed that weight loss held up over two years. At 104 weeks, semaglutide-treated participants maintained an average loss of about 15%, and over three-quarters had lost at least 5% of their starting weight.5Nature Medicine. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial The STEP 4 trial tested what happens when you stop mid-course: participants who continued semaglutide after an initial run-in period lost about 17% total, while those switched to placebo gained most of their weight back, netting only about 5%.6JAMA. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial That pattern of rebound is central to the risk discussion, because it means most people will need to stay on the drug long-term to keep the weight off.
The Most Common Side Effects
Gut symptoms dominate the side-effect profile. Nausea, vomiting, diarrhea, constipation, and a general feeling of fullness that tips into discomfort are all common, especially in the first weeks and when the dose is increased.7PubMed Central. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions These effects are dose-dependent and typically tied to the same mechanism that makes the drug work: slowed stomach emptying. In clinical trials, most participants found the nausea tolerable and it faded over time, but a subset stopped the medication because of persistent gut symptoms.
Gradual dose increases are the standard strategy for managing this. Manufacturers recommend starting at a low dose and stepping up over several weeks. Evidence on managing gastrointestinal symptoms is mostly practical rather than rigorously tested: eat smaller meals, stay hydrated, avoid fatty or greasy foods, and slow down at the table. If symptoms are severe, stepping back to the previous dose and trying again later often helps.8The Lancet. Is Ozempic Safe for Weight Loss? Risks Explained Anyone who experiences persistent vomiting, as opposed to mild nausea, should contact their prescriber rather than pushing through.
Serious Gastrointestinal Complications
Beyond routine nausea, a small number of people develop more severe problems. A large pharmacoepidemiological study found that GLP-1 agonist users had roughly four times the risk of gastroparesis and bowel obstruction, and about nine times the risk of pancreatitis, compared with users of another weight-loss drug (bupropion-naltrexone).9JAMA. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Those relative risks sound alarming, but the absolute numbers matter: pancreatitis and bowel obstruction remain rare events overall. Still, if you have a personal or family history of pancreatitis, this is something your doctor should weigh carefully.
Gastroparesis, where the stomach essentially stops emptying on schedule, has been documented in case reports among semaglutide users. The mechanism likely involves overstimulation of the same GLP-1 receptors that slow stomach motility under normal circumstances.10PubMed Central. Tendency of Semaglutide to Induce Gastroparesis: A Case Report A broad review of gastrointestinal safety data across GLP-1 drugs noted that evidence for these complications is “heterogeneous and sometimes conflicting,” meaning some studies find elevated risk and others do not, which makes precise risk estimates difficult.11PubMed Central. Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations The practical takeaway is that unexplained severe abdominal pain, recurrent vomiting, or an inability to keep food down are symptoms that warrant prompt medical evaluation.
Gallbladder Risks
A meta-analysis of semaglutide and tirzepatide trials in people with obesity (without diabetes) found that semaglutide increased gallbladder-related disorders, particularly gallstones, by over 2.5 times compared to placebo.12PubMed Central. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis Rapid weight loss from any cause is known to increase gallstone risk, so it is hard to separate the drug’s direct effect from the effect of losing weight quickly. If you have a history of gallbladder disease, your doctor should factor that in. Signs to watch for include sudden pain in the upper right abdomen, especially after meals, which can indicate gallstones or cholecystitis.
Thyroid Cancer Concerns
Ozempic’s prescribing label carries a boxed warning about thyroid C-cell tumors, based on findings in rodent studies where GLP-1 drugs caused thyroid tumors in rats and mice. This warning understandably worries people, but the relevance to humans is uncertain. A systematic review covering ten studies with large sample sizes found that thyroid cancer incidence among semaglutide users was very low, with isolated cases of papillary and medullary thyroid carcinoma each making up less than 1% of participants, suggesting no significant elevated risk.13PubMed Central. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review As a precaution, semaglutide is not recommended for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Eye Risks Worth Knowing About
A signal that received media attention in 2024 is the potential link between semaglutide and a condition called nonarteritic anterior ischemic optic neuropathy (NAION), a sudden loss of blood flow to the optic nerve that can cause permanent vision loss. An initial study found a higher rate of NAION among semaglutide users, though the researchers noted they could not identify a mechanism to explain the link and that patients with diabetic retinopathy already face higher risk of eye complications when blood sugar drops quickly.14JAMA Ophthalmology. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
A subsequent meta-analysis pooling the available data found a roughly 2.6-fold increased risk of NAION in semaglutide users, with the risk becoming statistically significant after about two years of use. Key risk factors included older age, male sex, longer diabetes duration, and existing diabetic retinopathy.15PubMed. Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence NAION is still uncommon overall, but for people with diabetes and existing eye disease, this is a risk to discuss with both an endocrinologist and an ophthalmologist.
The Psychiatric Side-Effect Debate
Reports of depression, anxiety, and suicidal thoughts among GLP-1 drug users have generated concern. An analysis of adverse-event reports submitted to the European drug safety database found that depression was the most commonly reported psychiatric event associated with semaglutide, followed by anxiety and suicidal ideation.16PubMed Central. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database A separate analysis of the U.S. FDA’s adverse event database found that semaglutide, but not tirzepatide, showed statistically elevated reporting rates for both depression and suicidal or self-injury events.17PubMed. Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database
A large retrospective study went further, reporting that patients on GLP-1 drugs had roughly double the risk of psychiatric disorders overall, including a nearly threefold higher risk of major depression compared with controls.18Scientific Reports. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy The proposed explanation involves changes in dopamine signaling: GLP-1 receptors in the brain’s reward circuits may alter dopamine availability, potentially contributing to anhedonia and low mood.
There is a major caveat here. Adverse-event databases capture reports, not proven causation, and people with obesity already have elevated rates of depression and anxiety independent of any medication. The data is concerning enough that the European Medicines Agency reviewed it in 2023, and clinicians should screen for mood changes, but it has not been definitively established that semaglutide causes psychiatric illness as opposed to being taken by a population already at higher risk. If you have a history of depression or suicidal thoughts, it makes sense to have a monitoring plan in place before starting treatment.
Muscle Loss and Body Composition
One of the less-discussed risks of semaglutide is the loss of lean mass alongside fat. In one study tracking body composition changes over a year, total fat mass dropped by about 19%, but lean mass also fell, by about 3 kilograms in the first seven months, before stabilizing.19PubMed Central. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study The proportion of lean mass relative to total body weight actually increased, because fat dropped faster, but losing muscle in absolute terms is still a concern, especially for older adults or anyone already dealing with low muscle mass.
A meta-analysis confirmed this pattern: fat loss accounted for the majority of weight lost, but lean mass declined at a smaller but consistent rate.20medRxiv. Body Composition Changes with Semaglutide: A Systematic Review and Meta-Analysis Another study found that roughly 30% of total weight lost was muscle mass.21Metabolism and Target Organ Damage. Effects of once-weekly semaglutide on regional body composition in overweight or obese adults This is why resistance training and adequate protein intake are considered essential companions to GLP-1 therapy, not optional add-ons. The drug reduces your appetite, so every calorie you do eat needs to count, and strength training sends a signal to your body to preserve muscle even when overall weight is dropping.
Nutritional Deficiencies on Reduced Calorie Intake
Because semaglutide suppresses appetite so effectively, many people end up eating far fewer calories than they need to meet basic nutritional requirements. Observed calorie reductions range from about 16% to 39%, and when intake drops below roughly 1,200 calories per day for women or 1,800 for men, the risk of vitamin and mineral deficiencies climbs steeply.22PubMed Central. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society Iron, calcium, magnesium, zinc, and several vitamins are among the nutrients most likely to fall short. Signs that something is off include fatigue beyond what you would expect from eating less, unusual hair loss, skin problems, muscle weakness, and slow wound healing.
A joint advisory from four major nutrition and obesity organizations emphasized that these consequences are “largely preventable with proper guidance,” but that many patients receive little or no dietary counseling alongside their GLP-1 prescription.23PubMed Central. Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care A separate statement from the same coalition noted that nutritional management, resistance training, and complementary lifestyle changes are critical during GLP-1 use to prevent deficiencies and preserve muscle and bone.24PubMed Central. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society If your prescriber does not bring up nutrition, ask about it yourself, or get a referral to a dietitian.
What Happens When You Stop
Weight regain after discontinuation is one of the most predictable outcomes with semaglutide. In the STEP 1 trial extension, participants who stopped the drug after 68 weeks regained about two-thirds of the weight they had lost within the following year. By week 120, the net weight loss from baseline was only about 5.6%, compared with nearly 15% at the end of treatment. Improvements in blood pressure, cholesterol, and blood sugar also reverted toward baseline.25PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
A smaller study in people with HIV saw a similar pattern: after stopping low-dose semaglutide at 24 weeks, participants regained an average of about 3 kilograms in the next 24 weeks, along with increases in waist circumference and fasting blood sugar.26PubMed Central. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV This rebound effect is not unique to semaglutide; it is the norm for pharmacological weight-loss interventions. But it shapes the risk calculus significantly, because long-term use means long-term exposure to all the risks described above. Anyone considering semaglutide should go in understanding that this is likely a commitment measured in years, not months.
Pregnancy and Fertility Considerations
Semaglutide is not approved for use during pregnancy. Animal studies raised concerns about fetal harm, though human data so far has been more reassuring: preliminary evidence from clinical trials and observational data suggests that inadvertent exposure during the first trimester does not appear to increase the risk of major birth defects, although the evidence base is limited.27Clinical Medicine and Health Research Journal. The Ozempic Pregnancy Phenomenon: What Medical Research Reveals Because semaglutide has a long half-life of about a week, it lingers in the body for weeks after the last injection. Regulatory authorities recommend stopping the drug at least two months before attempting to conceive, with reliable contraception in the interim.28PubMed Central. GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review
There is an ironic twist here. Semaglutide’s weight loss can improve fertility in women with polycystic ovary syndrome or obesity-related anovulation, sometimes resulting in unplanned pregnancies, an outcome colloquially called “Ozempic babies.” That makes preconception planning and contraception counseling especially important for anyone of reproductive age taking the drug.
Cardiovascular Benefits
One of the strongest arguments in semaglutide’s favor, independent of weight loss, is its cardiovascular benefit. The SELECT trial, a large study of people with obesity and established cardiovascular disease, found that semaglutide reduced the rate of heart attacks, strokes, and cardiovascular deaths. Research led by University College London further showed that this cardiovascular benefit was largely independent of how much weight a person actually lost, suggesting the drug has direct effects on heart disease processes beyond simply reducing body fat.29University College London. Ozempic and Wegovy protect the heart, even without weight loss For people with both obesity and heart disease risk, this benefit can tip the overall safety equation in favor of treatment, even accounting for the gastrointestinal and other risks.
The Compounded Semaglutide Problem
Shortages of branded Ozempic and Wegovy led to a surge in compounded versions, mixed by specialty pharmacies rather than manufactured by the original drugmaker. An analysis of the FDA’s adverse event database found that compounded GLP-1 products were associated with significantly higher rates of serious complications. Compared with brand-name products, compounded versions showed nearly triple the reporting rate for abdominal pain, more than six times the rate for suicidal ideation, and over triple the rate for cholecystitis. Reports of preparation errors, contamination, and compounding problems were dramatically higher, and hospitalization rates were more than double.30PubMed. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Compounded semaglutide is cheaper and more accessible during shortages, but these safety signals are a real trade-off. The FDA has repeatedly warned consumers about compounded versions, and if you choose that route, verifying the pharmacy’s credentials and sterility standards is essential.
How Semaglutide Compares to Tirzepatide
Tirzepatide (marketed as Mounjaro and Zepbound) works on two gut hormone receptors rather than one, and head-to-head data consistently shows it produces more weight loss than semaglutide. A meta-analysis of direct comparison studies found that tirzepatide produced about four additional percentage points of weight loss on average, and participants on tirzepatide were substantially more likely to reach the 10%, 15%, and 20% loss thresholds.31PubMed Central. Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies Real-world data from a large U.S. cohort confirmed this advantage, with the gap between the two drugs widening over time: by 12 months, tirzepatide users had lost about 7 percentage points more body weight than semaglutide users.32JAMA Internal Medicine. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
The gastrointestinal side-effect profile of the two drugs is broadly similar, and the gallbladder and pancreatic concerns apply to the GLP-1 class as a whole, though early meta-analysis data suggested tirzepatide may not carry the same elevated gallbladder risk that semaglutide does.12PubMed Central. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis If semaglutide’s efficacy is not enough, or if certain side effects are a problem, tirzepatide is the most common next consideration. But it comes with its own cost and availability challenges.
Who Should Be Especially Cautious
Certain groups face elevated risk with semaglutide and need closer monitoring or may need to avoid the drug altogether. A narrative review on risk mitigation highlighted several patient-specific vulnerabilities that should guide prescribing decisions.33PubMed Central. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation
- History of pancreatitis: the elevated risk of pancreatic inflammation makes semaglutide a poor choice for people who have had acute pancreatitis before.
- Gallbladder disease: if you have had gallstones or a cholecystectomy, discuss whether the added biliary risk changes your calculus.
- Diabetic retinopathy: rapid improvement in blood sugar can paradoxically worsen existing eye disease, and the emerging NAION signal adds another layer of concern.
- Older adults and those with low muscle mass: lean mass loss on semaglutide can accelerate sarcopenia, making falls and functional decline more likely. Resistance exercise and protein-rich eating are non-negotiable in this group.
- Anyone planning pregnancy: stop the drug well before conceiving, use contraception in the meantime, and discuss timing with your prescriber.
- People with a history of depression or suicidal ideation: while causation is not proven, the psychiatric safety signals warrant close mental health monitoring during treatment.
Off-label Ozempic use for weight loss is widespread partly because many insurance plans will not cover the weight-management brand (Wegovy), even when it is medically appropriate.34Elsevier / Clinical Therapeutics. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management This insurance gap means some people end up on doses or formulations that were not specifically studied for their situation, which can complicate risk assessment. If you are using Ozempic off-label, make sure your prescriber is titrating your dose with weight management in mind, not just using a diabetes dosing schedule.